PE20170937A1 - Nuevos activadores de la guanilato ciclasa soluble y su uso - Google Patents

Nuevos activadores de la guanilato ciclasa soluble y su uso

Info

Publication number
PE20170937A1
PE20170937A1 PE2017000478A PE2017000478A PE20170937A1 PE 20170937 A1 PE20170937 A1 PE 20170937A1 PE 2017000478 A PE2017000478 A PE 2017000478A PE 2017000478 A PE2017000478 A PE 2017000478A PE 20170937 A1 PE20170937 A1 PE 20170937A1
Authority
PE
Peru
Prior art keywords
alkyl
piperidine
refers
soluble
cyclase
Prior art date
Application number
PE2017000478A
Other languages
English (en)
Spanish (es)
Inventor
Anne Marie Jeanne Bouillot
Nerina Dodic
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PE20170937A1 publication Critical patent/PE20170937A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
PE2017000478A 2014-09-19 2015-09-18 Nuevos activadores de la guanilato ciclasa soluble y su uso PE20170937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462052537P 2014-09-19 2014-09-19

Publications (1)

Publication Number Publication Date
PE20170937A1 true PE20170937A1 (es) 2017-07-13

Family

ID=54238488

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000478A PE20170937A1 (es) 2014-09-19 2015-09-18 Nuevos activadores de la guanilato ciclasa soluble y su uso

Country Status (21)

Country Link
US (2) US9938260B2 (enExample)
EP (1) EP3194384A1 (enExample)
JP (3) JP6678656B2 (enExample)
KR (1) KR20170054508A (enExample)
CN (1) CN106687456B (enExample)
AU (1) AU2015319724B2 (enExample)
BR (1) BR112017005660A2 (enExample)
CA (1) CA2961745A1 (enExample)
CL (1) CL2017000640A1 (enExample)
CO (1) CO2017002506A2 (enExample)
CR (1) CR20170102A (enExample)
DO (1) DOP2017000073A (enExample)
EA (1) EA033697B1 (enExample)
IL (1) IL251094A0 (enExample)
MA (1) MA40583A (enExample)
MX (1) MX2017003621A (enExample)
PE (1) PE20170937A1 (enExample)
PH (1) PH12017500481A1 (enExample)
SG (1) SG11201701915TA (enExample)
WO (1) WO2016042536A1 (enExample)
ZA (1) ZA201701835B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2685230C2 (ru) 2014-02-06 2019-04-17 Хептарес Терапьютикс Лимитед Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
EA033697B1 (ru) * 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение
WO2016042084A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 inhibitors
US11331308B2 (en) 2016-10-11 2022-05-17 Bayer Pharma Aktiengesellschaft Combination containing sGC activators and mineralocorticoid receptor antagonists
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
CN112055584A (zh) 2018-04-30 2020-12-08 拜耳公司 sGC活化剂和sGC刺激剂用于治疗认知障碍的用途
MA52616A (fr) 2018-05-15 2021-03-24 Bayer Ag Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
WO2020148379A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
CN119300815A (zh) 2022-06-09 2025-01-10 拜耳公司 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
JP5411703B2 (ja) * 2006-11-09 2014-02-12 アルコン リサーチ, リミテッド 薬物送達のための水不溶性ポリマーマトリクス
PE20091258A1 (es) * 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
CA2753434C (en) 2009-02-26 2014-07-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
JP5636296B2 (ja) 2011-01-20 2014-12-03 公益財団法人微生物化学研究会 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体
EA033697B1 (ru) * 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение

Also Published As

Publication number Publication date
JP2020105189A (ja) 2020-07-09
CN106687456B (zh) 2019-12-03
AU2015319724B2 (en) 2018-05-10
US20170305888A1 (en) 2017-10-26
MA40583A (fr) 2016-03-24
ZA201701835B (en) 2018-12-19
DOP2017000073A (es) 2017-04-16
JP6678656B2 (ja) 2020-04-08
EA033697B1 (ru) 2019-11-18
MX2017003621A (es) 2017-07-14
JP2017527602A (ja) 2017-09-21
KR20170054508A (ko) 2017-05-17
WO2016042536A1 (en) 2016-03-24
US9938260B2 (en) 2018-04-10
CA2961745A1 (en) 2016-03-24
CL2017000640A1 (es) 2017-10-06
BR112017005660A2 (pt) 2017-12-19
JP6908747B2 (ja) 2021-07-28
SG11201701915TA (en) 2017-04-27
IL251094A0 (en) 2017-04-30
US10472350B2 (en) 2019-11-12
CO2017002506A2 (es) 2017-07-28
EP3194384A1 (en) 2017-07-26
CR20170102A (es) 2017-07-17
US20180194756A1 (en) 2018-07-12
JP2021155450A (ja) 2021-10-07
EA201790655A1 (ru) 2017-08-31
AU2015319724A1 (en) 2017-04-06
CN106687456A (zh) 2017-05-17
PH12017500481A1 (en) 2017-08-07

Similar Documents

Publication Publication Date Title
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20210040A1 (es) Moduladores de la via de estres integrada
PE20170697A1 (es) Indazoles sustituidos con benzilo como inhibidores de bub1
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20170444A1 (es) Herbicidas de piperidinona
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20141691A1 (es) Compuestos con actividad nematicida
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20170326A1 (es) Herbicidas de piridazinona
AR061644A1 (es) Derivados de benzofurano
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
PE20151538A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20191142A1 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
PE20200608A1 (es) Nuevos derivados de azaquinolina
PE20090417A1 (es) Compuestos de piperazina con accion herbicida
PE20130155A1 (es) Derivados de ariletinilo
PE20161552A1 (es) Compuestos de dihidroisoquinolinona sustituida
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20161143A1 (es) Derivados de pirimidiniloxi benceno como herbicidas